Dietary manipulation of histone structure and function

World Review of Nutrition and Dietetics

Volumn 101, Issue , 2010, Pages 95-102

  Ho, Emily ^a,b   Dashwood, Roderick H ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE DEACETYLASE INHIBITOR;

DNA METHYLATION; GENETIC EPIGENESIS; HUMAN; METABOLISM; NUTRIGENOMICS; PHYSIOLOGY; REVIEW;

DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; NUTRIGENOMICS;

EID: 84926108072     PISSN: 00842230     EISSN: 16623975     Source Type: Book Series    
DOI: 10.1159/000314514     Document Type: Conference Paper

References (50)

1. Seligson DB, Horvath S, Shi T, et al: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-1266.
2. Sigalotti L, Fratta E, Coral S, et al: Epigenetic drugs as pleiotropic agents in cancer treatment: biomolec-ular aspects and clinical applications. J Cell Physiol 2007;212:330-344.
3. Fronsdal K, Saatcioglu F: Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 2005;62:299-306.
4. Butler LM, Agus DB, Scher HI, et al: Suberoylanilide hydroxamic acid, an inhibitor of histone deacety-lase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-5170.
5. Li D, Ye a S, Dolios G, et al: Regulation of Kruppel-like factor 6 tumor suppressor activity by acetyla-tion. Cancer Res 2005;65:9216-9225.
6. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC: Aberrant methylation and deacetyla-tion of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res 2006;12:1412-1419
7. Soucek K, Kamaid A, Phung AD, et al: Normal and prostate cancer cells display distinct molecular profiles of alpha-tubulin posttranslational modifications. Prostate 2006;66:954-965.
8. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004;101: 540-545.
9. Brinkmann H, Dahler AL, Popa C, et al: Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem 2001; 276:22491-22499.
10. Vannini A, Volpari C, Filocamo G, et al: Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004;101:15064-15069.
11. Balasubramanian S, Verner E, Buggy JJ: Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009;280:211-221.
12. Garcia-Manero G, Issa JP: Histone deacetylase inhibitors: a review of their clinical status as antine-oplastic agents. Cancer Invest 2005;23:635-642.
13. Wiltse J: Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin: developmental effects of valproic acid. Crit Rev Toxicol 2005;35: 727-738.
14. O'Connor OA, Heaney ML, Schwartz L, et al: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24:166-173.
15. Kelly WK, O'Connor OA, Krug LM, et al: Phase I study of an oral histone deacetylase inhibitor, sube-roylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-3931.
16. Finnin MS, Donigian JR, Cohen A, et al: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-193
17. Furumai R, Komatsu Y, Nishino N, et al: Potent his-tone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 2001;98:87-92.
18. Dashwood RH, Ho E: Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 2007;17:363-369.
19. Myzak MC, Karplus PA, Chung F-L, Dashwood RH: A novel mechanism of chemoprotection by sul-foraphane: inhibition of histone deacetylase. Cancer Res 2004;64:5767-5774.
20. Myzak MC, Ho E, Dashwood RH: Dietary agents as histone deacetylase inhibitors. Mol Carcinog 2006; 45:443-446.
21. Myzak MC, Karplus PA, Chung FL, Dashwood RH: A novel mechanism of chemoprotection by sul-foraphane: inhibition of histone deacetylase. Cancer Res 2004;64:5767-5774.
22. Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E: Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis 2006;27:811-819.
23. Pledgie-Tracy A, Sobolewski MD, Davidson NE: Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 2007;6:1013-1021.
24. Dashwood RH, Ho E: Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 2007;17:363-369.
25. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E: Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 2007; 232:227-234.
26. Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH: Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. Faseb J 2006;20:506-508.
27. Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr 2003;133:2485S-2493S.
28. Sekhavat A, Sun JM, Davie JR: Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem Cell Biol 2007;85:751-758.
29. Druesne N, Pagniez A, Mayeur C, et al.: Diallyl dis-ulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 2004;25:1227-1236.
30. Nian H, Delage B, Pinto JT, Dashwood RH: Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcino-genesis 2008;29:1816-1824.
31. Lee JI, Nian H, Cooper AJ, et al: Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res 2009; 2:683-693.
32. Nian H, Bisson WH, Dashwood WM, Pinto JT, Dashwood RH: Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacety-lase activity in human colon cancer cells. Carcinogenesis 2009;30:1416-1423.
33. Turker MS, Bestor TH: Formation of methylation patterns in the mammalian genome. Mutat Res 1997;386:119-130.
34. Jones PA, Baylin SB: The fundamental role of epige-netic events in cancer. Nat Rev Genet 2002;3:415-428.
35. Wolffe AP, Matzke MA: Epigenetics: regulation through repression. Science 1999;286:481-486.
36. Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005;2(suppl 1):S4-S11.
37. Baylin SB, Esteller M, Rountree MR, et al: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-692.
38. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
39. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
40. Li LC, Carroll PR, Dahiya R: Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005;97:103-115.
41. Dobosy JR, Selker EU: Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 2001;58:721-727.
42. Ng HH, Zhang Y, Hendrich B, et al: MBD2 is a tran-scriptional repressor belonging to the MeCP1 his-tone deacetylase complex. Nat Genet 1999;23: 58-61.
43. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T: DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000;24:88-91.
44. Gore SD, Baylin S, Sugar E, et al: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-6369.
45. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and his-tone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-107.
46. Ghoshal K, Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 2007; 43:395-422.
47. Juttermann R, Li E, Jaenisch R: Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyl-transferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-11801.
48. Wang LG, Beklemisheva A, Liu XM, et al: Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog 2007;46:24-31.
49. Myzak MC, Dashwood RH: Chemoprotection by sulforaphane: keep one eye beyond Keap1. Cancer Lett 2006;233:208-218.
50. Nian H, Delage B, Ho E, Dashwood RH: Modulation of histone deacetylase activity by dietary isothiocya-nates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen 2009;50:213-221.